| Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy (NCT01679119) | University College, London | 2013-10-01 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) (NCT01804686) | Janssen Research & Development, LLC | 2013-09-09 |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies (NCT01796470) | Gilead Sciences | 2013-06-20 |
| Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas (NCT01793233) | Children's Oncology Group | 2013-06-17 |
| R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B (NCT01852435) | Ruijin Hospital | 2013-05-01 |
| Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma (NCT02268045) | mAbxience Research S.L. | 2013-05-01 |
| A Phase I Trial of AZD3965 in Patients With Advanced Cancer (NCT01791595) | Cancer Research UK | 2013-04-23 |
| Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies (NCT01799889) | Gilead Sciences | 2013-03-14 |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency (NCT01787409) | Mayo Clinic | 2013-03-06 |
| Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia (NCT01842672) | New York Medical College | 2013-03-01 |
| Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (NCT01944943) | The Lymphoma Academic Research Organisation | 2013-02-01 |
| Dose-adjusted EPOCH-R in MYC Positive DLBCL (NCT01914718) | Fudan University | 2013-02-01 |
| Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (NCT01760226) | Baylor College of Medicine | 2013-01-01 |
| Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma (NCT02060435) | Samsung Medical Center | 2013-01-01 |
| A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) (NCT01713582) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-12-14 |
| Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse (NCT01562990) | The Lymphoma Academic Research Organisation | 2012-12-01 |
| An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma (NCT01724294) | Hoffmann-La Roche | 2012-12-01 |
| A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (NCT01691898) | Genentech, Inc. | 2012-09-27 |
| Treatment of Diffuse Large B Cell Lymphoma (NCT01949818) | Mingzhi Zhang | 2012-09-01 |
| STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma (NCT01653067) | Mathias Witzens-Harig | 2012-09-01 |
| Erythropoietin for Management of Anemia Caused by Chemotherapy (NCT02890602) | Kosin University Gospel Hospital | 2012-09-01 |
| Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. (NCT01670370) | The First Affiliated Hospital with Nanjing Medical University | 2012-08-01 |
| Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over (NCT02792491) | Pusan National University Hospital | 2012-08-01 |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT01741792) | Amgen Research (Munich) GmbH | 2012-07-01 |
| BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology (NCT01660776) | Rennes University Hospital | 2012-06-07 |
| Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (NCT01622439) | Lund University Hospital | 2012-06-01 |
| Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy (NCT01510184) | Spectrum Pharmaceuticals, Inc | 2012-04-19 |
| A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT01453205) | MedImmune LLC | 2012-02-27 |
| Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT00978432) | Anne Beaven, MD | 2012-02-01 |
| Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial (NCT01534949) | Celltrion | 2012-02-01 |
| SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients (NCT01472887) | Sanofi | 2012-01-01 |
| R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients (NCT03364439) | Fondazione Italiana Linfomi - ETS | 2012-01-01 |
| Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma (NCT01715961) | Centre Henri Becquerel | 2012-01-01 |
| Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer (NCT01499303) | AstraZeneca | 2011-12-01 |
| Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT01481129) | National Cancer Institute (NCI) | 2011-12-01 |
| Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients (NCT01481272) | Polish Lymphoma Research Group | 2011-11-01 |
| Communication Skills Intervention to Promote Transition Into Survivorship (NCT01483664) | Memorial Sloan Kettering Cancer Center | 2011-11-01 |
| Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (NCT01466868) | Centre Leon Berard | 2011-11-01 |
| Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01470456) | Sanofi | 2011-11-01 |
| MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine (NCT01397825) | Millennium Pharmaceuticals, Inc. | 2011-08-09 |
| MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma (NCT01415765) | National Cancer Institute (NCI) | 2011-07-15 |
| Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (NCT01282476) | Massachusetts General Hospital | 2011-06-01 |
| The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma. (NCT01865058) | Odense University Hospital | 2011-06-01 |
| Imexon for Relapsed Follicular and Aggressive Lymphomas (NCT01314014) | University of Rochester | 2011-05-01 |
| Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (NCT01321541) | CTI BioPharma | 2011-04-20 |
| Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL (NCT01562977) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2011-04-01 |
| Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) (NCT02412267) | National Cancer Centre, Singapore | 2011-04-01 |
| Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT (NCT01523834) | Fondazione Italiana Linfomi - ETS | 2011-02-01 |
| An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma (NCT01340443) | Hoffmann-La Roche | 2011-01-19 |
| Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma (NCT02340936) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2011-01-01 |
| Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma (NCT01606605) | Samsung Medical Center | 2011-01-01 |
| R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma (NCT01278602) | Fudan University | 2010-12-01 |
| A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) (NCT01238692) | Sarit Assouline | 2010-11-01 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma (NCT01226849) | Singapore General Hospital | 2010-11-01 |
| Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL (NCT01241734) | Hackensack Meridian Health | 2010-10-01 |
| TREatment of degeNerative and Neoplastic Diseases With Rituximab (NCT01277172) | Probiomed S.A. de C.V. | 2010-10-01 |
| Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma (NCT01186978) | Duke University | 2010-09-20 |
| Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (NCT01197560) | Celgene | 2010-09-02 |
| Tandem Auto-Allo Transplant for Lymphoma (NCT01181271) | Massachusetts General Hospital | 2010-08-01 |
| Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma (NCT01202448) | Samsung Medical Center | 2010-08-01 |
| Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL (NCT01279902) | Asan Medical Center | 2010-08-01 |
| Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma (NCT01177397) | Celgene | 2010-07-20 |
| A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. (NCT01144403) | Hoffmann-La Roche | 2010-06-01 |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL (NCT01101581) | Gilead Sciences | 2010-05-01 |
| Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma (NCT01009970) | Fondazione Italiana Linfomi - ETS | 2010-05-01 |
| Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma (NCT01040871) | Millennium Pharmaceuticals, Inc. | 2010-01-01 |
| Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma (NCT01004991) | Weill Medical College of Cornell University | 2010-01-01 |
| Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas (NCT01030900) | National Cancer Institute (NCI) | 2009-10-22 |
| Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy (NCT00790036) | Novartis Pharmaceuticals | 2009-07-24 |
| A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT00918463) | Weill Medical College of Cornell University | 2009-06-01 |
| Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (NCT00869999) | Massachusetts General Hospital | 2009-05-01 |
| Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP (NCT01122472) | The Lymphoma Academic Research Organisation | 2009-04-01 |
| Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT00968331) | University of Bologna | 2009-03-01 |
| Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma (NCT00799513) | IRCCS San Raffaele | 2009-03-01 |
| CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma (NCT00924326) | National Cancer Institute (NCI) | 2009-02-17 |
| Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma (NCT00807495) | Millennium Pharmaceuticals, Inc. | 2009-02-10 |
| Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma (NCT01369784) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2009-02-01 |
| Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL (NCT04160442) | Carevive Systems, Inc. | 2009-01-16 |
| Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1 (NCT00968656) | Washington University School of Medicine | 2009-01-01 |
| A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma (NCT00794638) | SymBio Pharmaceuticals | 2008-11-01 |
| Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT00831597) | Pharmatech | 2008-11-01 |
| Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer (NCT00789776) | Fred Hutchinson Cancer Center | 2008-10-13 |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies (NCT00697346) | Millennium Pharmaceuticals, Inc. | 2008-07-11 |
| Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT00836173) | Loyola University | 2008-07-01 |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma (NCT00644189) | Massachusetts General Hospital | 2008-06-01 |
| Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET) (NCT00754117) | Weill Medical College of Cornell University | 2008-05-01 |
| Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) (NCT00607854) | University Hospital, Bordeaux | 2008-02-01 |
| Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (NCT00599170) | University of Southern California | 2008-01-10 |
| Zevalin Twice in Aggressive Non-Hodgkin Lymphoma (NCT00902525) | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | 2008-01-01 |
| A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients (NCT01793844) | Sun Yat-sen University | 2008-01-01 |
| Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma (NCT00575406) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2007-12-01 |
| Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients (NCT00846157) | NKBio Co.Ltd. | 2007-09-01 |
| Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis (NCT00553943) | Lymphoma Study Association | 2007-07-01 |
| FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma (NCT00530179) | AHS Cancer Control Alberta | 2007-07-01 |
| A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT00474188) | Celgene Corporation | 2007-05-01 |
| Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma (NCT00645359) | University of Michigan Rogel Cancer Center | 2006-11-01 |
| Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma (NCT01459887) | Shanghai CP Guojian Pharmaceutical Co., Ltd. | 2006-09-01 |
| The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP (NCT00440583) | Mahidol University | 2006-09-01 |
| A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. (NCT00333008) | The Alvin and Lois Lapidus Cancer Institute | 2006-05-01 |